J.P. Morgan Raises PT on Thermo Fisher Scientific (TMO) Keeps an Overweight Rating

Group 1 - Thermo Fisher Scientific Inc. is considered one of the best long-term investment stocks, with J.P. Morgan raising its price target from $600 to $650 while maintaining an Overweight rating [1] - The company is set to report its fiscal third-quarter results on October 22, 2025, and analysts expect a conservative outlook for life sciences tool companies in 2026 due to pending evidence for order improvement [2] - Thermo Fisher has raised its full-year guidance, expecting revenue between $43.6 billion and $44.2 billion, and adjusted EPS between $22.22 and $22.84 per share [3]